Extremly low SHBG level in consequence of Pro156Leu SHBG polymorphism – case reports of two women with polycystic ovary syndrome

Česká verzia

Authors: M. Vaňková; S. Pražáková; P. Lukášová; J. Včelák; D. Vejražková; O. Bradnová; K. Dvořáková; J. Vrbíková; B. Bendlová
Authors place of work: Oddělení molekulární endokrinologie Endokrinologického ústavu Praha, ředitel doc. MU Dr. Vojtěch Hainer, CSc.
Published in the journal: Vnitř Lék 2010; 56(12): 1292-1295
Category: Celebration

Summary

Presented case reports illustrate clinical manifestations of two women with polycystic ovary syndrome who had extremly low serum SHBG levels (Sex Hormone Binding Globulin) due to homozygote carriership of the rare Pro156Leu SHBG polymorphism.

Key words:
SHBG – polymorphism – polycystic ovary syndrome

Zdroje

1. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approavh. In: Dunaif A, Givens JR, Haseltine FP et al (eds). Polycystic Ovary Syndrome. Boston: Blackwell Scientific 1992: 377– 384.

2. Rotterdam ESHRE/ ASRM‑ sponsored PCOS workshop group. Revised 2003 consensus on diagnostic criteria and long‑term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41– 47.

3. Azziz R, Carmina E, Dewailly D et al. Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91: 4237– 4245.

4. Azziz R. The polycystic ovary syndrome: Current concepts on Pathogenesis and clinical care. New York: Springer science + Business Media 2007.

5. Marshall K. Polycystic ovary syndrome: clinical considerations. Altern Med Rev 2001; 6: 272– 292.

6. Pugeat M, Nader N, Hogeveen K et al. Sex hormone‑binding globulin gene expression in the liver: drugs and the metabolic syndrome. Mol Cell Endocrinol 2010; 316: 53– 59.

7. De Leo V, Di Sabatino A, Musacchio MC et al. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. Contraception 2010; 82: 276– 280.

8. Xita N, Tsatsoulis A. Genetic variants of sex hormone‑binding globulin and their biological consequences. Mol Cell Endocrinol 2010; 316: 60– 65.

9. Nestler JE, Jakubowicz DJ, de Vargas AF et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998; 83: 2001– 2005.

10. Spaczynski RZ, Tilly JL, Mansour A et al. Insulin and insulin‑like growth factors inhibit and luteinizing hormone augments ovarian theca‑ interstitial cell apoptosis. Mol Hum Reprod 2005; 11: 319– 324.

11. Dunaif A, Green G, Futterweit W et al. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 1990; 70: 699– 704.

12. Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol 1989; 30: 459– 470.

13. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774– 800.

14. Codner E, Soto N, Lope P et al. Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 2250– 2256.

15. Kvasničková H, Vrbíková J, Hanáček J et al. Výskyt syndromu polycystických ovárií a hyperandrogenemie u pacientek s diabetes mellitus 1. typu. Prakt Lék 2010; 90: 224– 228.

16. Períková J, Lazúrová I. Syndróm polycystických ovárií a autoimunitné ochorenia. Vnitř Lék 2010; 56: 414– 417.